Form 4: Director Kevin O'Boyle Receives Outset Medical Equity Grant

Director Kevin O'Boyle was granted 10,667 restricted stock units (RSUs) by Outset Medical, Inc. on June 4, 2026.

Summary

• Director Kevin C. O'Boyle acquired 10,667 shares of common stock in the form of restricted stock units (RSUs).
• The transaction occurred on June 4, 2026, at a price of $0.0 per share.
• Following this transaction, the reporting person's total beneficial ownership increased to 34,785 shares of common stock.
• The RSUs are subject to a vesting schedule tied to the one-year anniversary of the grant or the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The RSUs will vest in full on the earlier of the one-year anniversary of the grant date or the date of the issuer's next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure long-term alignment with shareholder value in the medical device sector.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for publicly traded medical technology companies.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the 10,667 RSUs upon the earlier of the one-year anniversary or the next annual meeting.

Key Dates

Keywords

Outset Medical, OM, Form 4, Insider Transaction, Equity Grant, Director Compensation